JP7439280B2 - キメラ抗原受容体の最適化 - Google Patents
キメラ抗原受容体の最適化 Download PDFInfo
- Publication number
- JP7439280B2 JP7439280B2 JP2022549228A JP2022549228A JP7439280B2 JP 7439280 B2 JP7439280 B2 JP 7439280B2 JP 2022549228 A JP2022549228 A JP 2022549228A JP 2022549228 A JP2022549228 A JP 2022549228A JP 7439280 B2 JP7439280 B2 JP 7439280B2
- Authority
- JP
- Japan
- Prior art keywords
- cd3ζ
- cells
- car
- amino acid
- signaling domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title claims description 33
- 238000005457 optimization Methods 0.000 title description 2
- 230000011664 signaling Effects 0.000 claims description 62
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 19
- 230000019491 signal transduction Effects 0.000 claims description 19
- 210000004102 animal cell Anatomy 0.000 claims description 3
- 210000004027 cell Anatomy 0.000 description 58
- 238000006467 substitution reaction Methods 0.000 description 39
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 36
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 36
- 238000000034 method Methods 0.000 description 35
- 125000000539 amino acid group Chemical group 0.000 description 30
- 230000026731 phosphorylation Effects 0.000 description 23
- 238000006366 phosphorylation reaction Methods 0.000 description 23
- 210000001744 T-lymphocyte Anatomy 0.000 description 21
- 150000001413 amino acids Chemical class 0.000 description 20
- 230000035772 mutation Effects 0.000 description 20
- 230000004913 activation Effects 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 16
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 11
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 11
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 9
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 9
- 239000000427 antigen Substances 0.000 description 8
- 238000012217 deletion Methods 0.000 description 8
- 230000037430 deletion Effects 0.000 description 8
- 102200008771 rs121918549 Human genes 0.000 description 8
- 108010002350 Interleukin-2 Proteins 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 102220591763 Voltage-gated potassium channel subunit beta-3_Y90F_mutation Human genes 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 102220005275 rs33958358 Human genes 0.000 description 7
- 230000000139 costimulatory effect Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000004068 intracellular signaling Effects 0.000 description 6
- 210000005259 peripheral blood Anatomy 0.000 description 6
- 239000011886 peripheral blood Substances 0.000 description 6
- 230000002688 persistence Effects 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 208000032839 leukemia Diseases 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 102220068382 rs113886269 Human genes 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 206010061819 Disease recurrence Diseases 0.000 description 3
- 101000818543 Homo sapiens Tyrosine-protein kinase ZAP-70 Proteins 0.000 description 3
- 102000017578 LAG3 Human genes 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 108091008874 T cell receptors Proteins 0.000 description 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 3
- 102100021125 Tyrosine-protein kinase ZAP-70 Human genes 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 210000000225 synapse Anatomy 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000025321 B-lymphoblastic leukemia/lymphoma Diseases 0.000 description 2
- 101150030213 Lag3 gene Proteins 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000009437 off-target effect Effects 0.000 description 2
- 208000017426 precursor B-cell acute lymphoblastic leukemia Diseases 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000005909 tumor killing Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 206010050685 Cytokine storm Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108050003452 SH2 domains Proteins 0.000 description 1
- 102000014400 SH2 domains Human genes 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 206010052015 cytokine release syndrome Diseases 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000003318 immunodepletion Methods 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000717 sertoli cell Anatomy 0.000 description 1
- 102000009076 src-Family Kinases Human genes 0.000 description 1
- 108010087686 src-Family Kinases Proteins 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
(1)CD19を標的する抗原結合ドメイン、特に配列番号:2の第23~267位のアミノ酸、
(2)ヒンジ領域、特にCD28ヒンジ領域、特に配列番号:2の第268~307位のアミノ酸、
(3)膜貫通領域、特にCD28膜貫通領域、特に配列番号:2の第308~333位のアミノ酸、
(4)共刺激ドメイン、特にCD28共刺激ドメイン、特に配列番号:2の第334~374位のアミノ酸;および
(5)シグナル伝達ドメイン、特に改変CD3ζ、特に配列番号:6、8および10から選択されるアミノ酸配列
を含む。
実施例1 細胞内CD3ζシグナル伝達ドメインの改変
本発明のまた別の態様は、以下のとおりであってもよい。
〔1〕CD3ζ由来の改変シグナル伝達ドメインであって、
天然配列と比較して、前記改変シグナル伝達ドメインは、免疫受容体チロシン活性化モチーフにおける一つまたは複数のチロシンリン酸化部位の突然変異を含み、
任意選択的に、前記チロシンリン酸化部位は、配列番号:4のY21、Y32、Y59、Y71、Y90およびY101に対応する残基から選択され、
任意選択的に、前記突然変異は欠失または置換である、
ことを特徴とする、改変シグナル伝達ドメイン。
〔2〕Y90が削除されるかまたはFで置換され、特にY90がFで置換される、前記〔1〕に記載の改変シグナル伝達ドメイン。
〔3〕CD3ζ由来の改変シグナル伝達ドメインであって、
天然配列と比較して、前記改変シグナル伝達ドメインが、膜近傍領域における一つまたは複数のアミノ酸残基の突然変異を含み、
任意選択的に、前記膜近傍領域のアミノ酸残基は、配列番号:4のR1、V2、K3、F4、S5、R6、S7、A8、D9、A10、P11、A12、Y13、Q14、Q15、G16、Q17およびN18に対応する残基から選択され、
任意選択的に、前記突然変異は欠失または置換である、
ことを特徴とする、改変シグナル伝達ドメイン。
〔4〕V2が削除またはLで置換され、D9が削除またはEで置換され、および/またはQ15が削除またはKで置換され、特にQ15がKで置換される、前記〔3〕に記載の改変シグナル伝達ドメイン。
〔5〕CD3ζ由来の改変シグナル伝達ドメインであって、
天然配列と比較して、前記改変シグナル伝達ドメインは、免疫受容体チロシン活性化モチーフにおける一つまたは複数のチロシンリン酸化部位の突然変異を含み、
任意選択的に、前記チロシンリン酸化部位は、配列番号:4のY21、Y32、Y59、Y71、Y90およびY101に対応する残基から選択され、
且つ、前記改変シグナル伝達ドメインが、膜近傍領域の一つまたは複数のアミノ酸残基の突然変異を含み、
任意選択的に、前記膜近傍領域におけるアミノ酸残基は、配列番号:4のR1、V2、K3、F4、S5、R6、S7、A8、D9、A10、P11、A12、Y13、Q14、Q15、G16、Q17およびN18に対応する残基から選択され、
任意選択的に、前記突然変異は欠失または置換である、
ことを特徴とする、改変シグナル伝達ドメイン。
〔6〕改変シグナル伝達ドメインがY90F置換を含み、且つV2L、D9Eおよび/またはQ15K置換のうちの一つまたは複数を含み、特にV2L、Q15KおよびY90F置換、またはV2L、D9E、Q15KおよびY90F置換を含む、前記〔5〕に記載の改変シグナル伝達ドメイン。
〔7〕配列番号:6、8または10に示されるアミノ酸配列を含むか、本質的にそれからなるか、またはそれからなる、CD3ζ由来の改変シグナル伝達ドメイン。
〔8〕CD3ζ由来のシグナル伝達ドメインを改変する方法であって、
CD3ζシグナル伝達ドメインの免疫受容体チロシン活性化モチーフ内の一つまたは複数のチロシンリン酸化部位を突然変異させる工程、および/または
CD3ζシグナル伝達ドメインの膜近傍領域における一つまたは複数のアミノ酸残基を突然変異させる工程を含む、方法。
〔9〕前記〔1〕から〔7〕のいずれか一項に記載の改変シグナル伝達ドメインまたは前記〔8〕に記載の方法によって得られた改変シグナル伝達ドメインを含む、キメラ抗原受容体。
〔10〕前記〔9〕に記載のキメラ抗原受容体を含む、動物細胞。
〔11〕CD3ζ由来のシグナル伝達ドメインを含むキメラ抗原受容体を最適化する方法であって、
CD3ζシグナル伝達ドメインの免疫受容体チロシン活性化モチーフ内の一つまたは複数のチロシンリン酸化部位を突然変異させる工程、および/または
CD3ζシグナル伝達ドメインの膜近傍領域における一つまたは複数のアミノ酸残基を突然変異させる工程を含む、方法。
Claims (3)
- 配列番号:6、8または10に示されるアミノ酸配列からなる、CD3ζ由来の改変シグナル伝達ドメイン。
- 請求項1に記載のCD3ζ由来の改変シグナル伝達ドメインを含む、キメラ抗原受容体。
- 請求項2に記載のキメラ抗原受容体を含む、動物細胞。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010091790 | 2020-02-13 | ||
CN202010091790.4 | 2020-02-13 | ||
PCT/CN2021/076247 WO2021160124A1 (zh) | 2020-02-13 | 2021-02-09 | 嵌合抗原受体的优化 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2023513821A JP2023513821A (ja) | 2023-04-03 |
JP7439280B2 true JP7439280B2 (ja) | 2024-02-27 |
Family
ID=77292973
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022549228A Active JP7439280B2 (ja) | 2020-02-13 | 2021-02-09 | キメラ抗原受容体の最適化 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20230340063A1 (ja) |
EP (1) | EP4104850A4 (ja) |
JP (1) | JP7439280B2 (ja) |
CN (1) | CN115151272A (ja) |
AU (1) | AU2021219886A1 (ja) |
WO (1) | WO2021160124A1 (ja) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20180186855A1 (en) * | 2016-03-23 | 2018-07-05 | Alector Llc | Chimeric receptors and methods of use thereof |
JP2020526194A (ja) * | 2017-06-29 | 2020-08-31 | ジュノー セラピューティクス インコーポレイテッド | 免疫療法薬と関連する毒性を評価するためのマウスモデル |
SG11202007370RA (en) * | 2018-02-11 | 2020-08-28 | Univ California | Car-t cells and autoimmune diseases |
US20210322473A1 (en) * | 2018-07-18 | 2021-10-21 | The General Hospital Corporation | Modified t cells and methods of their use |
WO2021190551A1 (zh) * | 2020-03-25 | 2021-09-30 | 上海先博生物科技有限公司 | 结合cd19的嵌合抗原受体及其用途 |
-
2021
- 2021-02-09 CN CN202180013402.3A patent/CN115151272A/zh active Pending
- 2021-02-09 JP JP2022549228A patent/JP7439280B2/ja active Active
- 2021-02-09 WO PCT/CN2021/076247 patent/WO2021160124A1/zh unknown
- 2021-02-09 US US17/799,492 patent/US20230340063A1/en active Pending
- 2021-02-09 AU AU2021219886A patent/AU2021219886A1/en active Pending
- 2021-02-09 EP EP21752943.7A patent/EP4104850A4/en active Pending
Non-Patent Citations (1)
Title |
---|
ROHRS, Jennifer A. et al.,"Computational Model of Chimeric Antigen Receptors Explains Site-Specific Phosphorylation Kinetics",Biophysical Journal,2018年09月,Vol. 115, No. 6,pp.1116-1129,DOI: 10.1016/j.bpj.2018.08.018 |
Also Published As
Publication number | Publication date |
---|---|
WO2021160124A1 (zh) | 2021-08-19 |
JP2023513821A (ja) | 2023-04-03 |
CN115151272A (zh) | 2022-10-04 |
AU2021219886A1 (en) | 2022-08-25 |
US20230340063A1 (en) | 2023-10-26 |
EP4104850A1 (en) | 2022-12-21 |
EP4104850A4 (en) | 2023-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6161098B2 (ja) | Car発現ベクター及びcar発現t細胞 | |
JP2024069310A (ja) | キメラ受容体及びその使用方法 | |
CN112334193A (zh) | Dll3的嵌合受体及其使用方法 | |
CN113234682B (zh) | 靶向cd7的工程化免疫细胞、嵌合抗原受体、cd7阻断分子及应用 | |
TWI753141B (zh) | 嵌合抗原受體 | |
CN111320703A (zh) | 靶向cd22的嵌合抗原受体及其应用 | |
US20220073585A1 (en) | Chimeric antigen receptor memory-like (carml) nk cells and methods of making and using same | |
US11690874B2 (en) | Use of chimeric antigen receptor modified cells to treat autoimmune disease | |
CN115335407A (zh) | 结合cd19的嵌合抗原受体及其用途 | |
CN112521513B (zh) | 一种靶向cd19的嵌合抗原受体(car)及其应用 | |
CN112679618A (zh) | 一种靶向trbc1的人源化嵌合抗原受体、t细胞及用途 | |
JP7439280B2 (ja) | キメラ抗原受容体の最適化 | |
CN112457416B (zh) | 一种靶向bcma的嵌合抗原受体(car)及其应用 | |
JP7439279B2 (ja) | キメラ抗原受容体の最適化 | |
EP4176895A1 (en) | Targeting modules against il13ra2 or her2 for use in combination with a chimeric antigen receptor | |
US20230212257A1 (en) | Anti-cd171 chimeric antigen receptors | |
EP4296281A1 (en) | Targeting modules against cd123 and a tag for use in a method for stimulating a universal chimeric antigen receptor-mediated immune response in a mammal | |
KR20240035506A (ko) | 키메라 항원 수용체, 상기 수용체를 발현하는 세포, 상기 세포를 포함하는 의약 조성물, 상기 세포의 제조 방법, 및 상기 키메라 항원 수용체를 코딩하는 염기서열을 포함하는 폴리뉴클레오티드 또는 벡터 | |
KR20240034205A (ko) | 항EGFRviii 항체, 폴리펩타이드, 상기 폴리펩타이드를 발현하는 세포, 상기 세포를 포함하는 의약 조성물, 상기 세포의 제조 방법 및 상기 폴리펩타이드를 코딩하는 염기서열을 포함하는 폴리뉴클레오티드 또는 벡터 | |
WO2024059733A2 (en) | Chimeric antigen receptors binding nectin-4 | |
WO2024098037A1 (en) | Generation of cd3 expressing immune cells for use in conjunction with cd3 binding bispecific targeting agents | |
NZ757552B2 (en) | Chimeric antigen receptor | |
CN114195882A (zh) | Tcr及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220812 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230814 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20231113 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231220 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240115 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240214 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7439280 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |